Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Notable anticipated approvals for third quarter 2025 include: First SC version of Keytruda in the oncology setting First treatment for non-relapsing secondary progressive multiple sclerosis An off-the shelf gene therapy for a rare genetic condition caused by human papilloma virus A first-in-class agent for bronchiectasis, a chronic inflammatory lung condition A new mechanism of action for spinal muscular atrophy A hot topic in the drug pipeline that continues to garner significant attention is GLP-1s
Nutrition and Monitoring During GLP-1 Treatment Post-Surgery GLP-1 medications slow gastric emptying and reduce appetite, which can inadvertently lower calorie and nutrient intake in an already-restricted surgical anatomy
The drug led to an average weight loss of 70.3 pounds over 80 weeks in patients with obesity, with 45% of patients on 12 mg of the once-weekly injectable retatrutide losing up to 30% of their body weight, the drugmaker, Eli Lilly and Company, said in a news release
Additionally, LendingTree commissioned QuestionPro to conduct an online survey of 2,015 U.S
